简介:目的:探讨激光消融与电解治疗倒睫的疗效与安全性。方法:选取倒睫患者50例76眼,分为激光消融和电解治疗两组进行倒睫治疗,观察记录两组患者术后眼部刺激症状、并发症及复发情况,共观察6mo。结果:激光消融组一次治愈率81%,复发率19%,总治愈率94%;电解治疗组一次治愈率49%,复发率63%,总治愈率72%。激光消融组一次治愈率和总治疗率显著高于电解治疗组,其复发率低于电解治疗组,两组差异有统计学意义(P〈0.05)。激光消融组患者无特殊不适,治疗部位无瘢痕产生及皮肤色素脱失;电解治疗组患者5眼出现轻度瘢痕。结论:激光消融治疗倒睫成功率高,患者术中无不适症状,术后并发症少,是一种有效安全的临床治疗方法。
简介:AIM:ToinvestigatetheefficacyofFerrararings(FR)implantationinthetreatmentofkeratoconus.METHODS:Itwasaretrospectivecaseseriesdescriptivestudy.Thesamplewascomprisedof50patients79eyesdiagnosedwithprogressivekeratoconus.Thisincluded24(48%)malesand26(52%)femalesbetweentheageof13and44years.AllparticipantsunderwentsurgicalimplantationofFRintheperiodbetweenJanuary2009andSeptember2010atJordanUniversityHospital.Thoroughophthalmologicexaminationswereappliedtomeasurevitalvariablesforeachpathologicalconditionbeforeandaftersurgery.RESULTS:Findingsindicatedanoverallsignificantpostoperativeimprovementinbothuncorrectedvisualacuity(UCVA)andbestspectaclecorrectedvisualacuity(BSCVA)throughoutfollowupvisits.Moreover,resultsillustratedasignificantdecreaseinsphericalequivalent(SE)andkeratometricreadings(lower,higherandtheaverage).CONCLUSION:Surgicalinterventionstrategiesarebeingfrequentlydevelopedtomeettheneedsofpatientswithkeratoconus.TheimplantationofFerrararingshasproventobeasafeandfeasiblealternativeprocedureforthetreatmentofmild-moderatekeratoconusespeciallyforpatientswithcontactlensesintolerance.Wehavefoundthatthisprocedurehasimprovedvisualoutcomesinalleyesstudied.Nevertheless,furtherresearchisneededtoinvestigatelongtermoutcomes.
简介:目的分析评价眼科激光对视网膜静脉阻塞的疗效。方法对32例经眼底荧光血管照影明确诊断的视网膜静脉阻塞的患者采用光凝治疗,治疗后预约定期随诊,并复查各项检查。结果治疗后视力增加17例,不变者10例,稍下降者5例,黄斑水肿明显减轻者21例,占65.62%;不变者5例,占15.62%;消失者6例,占18.75%,激光治疗后较激光治疗前的暗点数增加者20例,占60%,暗点数减少5例,占15.62%,不变者7例,占21.87%。并发症:激光治疗前有新生血管者5例,术后2例完全退缩。结论视网膜静脉阻塞早期行激光治疗可促进出血吸收,缩短病程,降低新生血管及玻璃体病变等并发症,是切实可行的治疗方法。
简介:·Thetherapeuticeffectofselenium(Se)hasalreadybeenproveninthyroiddiseaseandthyroidassociatedophthalmopathy(TAO).InspiteofclearscientificproofofitsbenefitsinTAO,thereappearstobenoclearagreementamongthecliniciansregardingitsoptimumdose,durationofthetreatment,efficacyandsafetytodate.Inthisreview,theauthorsummarisesthefindingsof135Englishlanguagearticlespublishedonthissubjectoverthepastfourdecadesfrom1973to2013.TheregulationandmetabolismofthyroidhormonesrequireasteadysupplyofSeandrecentstudieshaverevealedseveralpossiblemechanismsbywhichSeimprovestheseverityofthyroiddiseaseandTAO.Thesemechanismsinclude1)inhibitoryeffectofHLA-DRmoleculeexpressiononthyrocytes;2)profoundreductionsofthyroidstimulatinghormone(TSH)receptorantibodies(TSHR-Ab)andTPOantibodies(TPO-Ab);3)preventionofdysregulationofcell-mediatedimmunityandBcellfunction;4)neutralisingreactiveoxygenspecies(ROS)andinhibitionofredoxcontrolprocessesrequiredfortheactivation,differentiationandactionoflymphocytes,macrophages,neutrophils,naturalkillercellsinvolvedinbothacuteandchronicorbitalinflammationinTAO;5)inhibitionofexpressionofproinflammatorycytokinesand6)inhibitionofprostaglandinandleukotrienesynthesis.AnincreasedoxidativestresshasbeenobservedinbothacuteandchronicphasesofthyroiddiseasewithraisedtissueconcentrationsofROS.ThebenefitsofSesupplementationinindividualswithTAOappeartobeproportionatetothedegreeofsystemicactivityofthethyroiddisease.ThemaximalbenefitofSesupplementationisthereforeseeninthesubjectswhoarehyperthyroid.RestorationofeuthyroidismisoneofthemaingoalsinthemanagementofTAOandwhenanti-thyroiddrugsarecombinedwithSe,thepatientswithGraves’disease(GD)andautoimmunethyroiditis(AIT)achievedeuthyroidismfasterthanthosetreatedwithanti-thyroiddrugsalone.SestatusofnormaladulthumanscanvarywidelyandSe